Research output: Contribution to journal › Article › peer-review
Original language | English |
---|---|
Pages (from-to) | 1993-2007 |
Number of pages | 15 |
Journal | Oral Diseases |
Volume | 27 |
Issue number | 8 |
Early online date | 26 Feb 2021 |
DOIs | |
Accepted/In press | 2021 |
E-pub ahead of print | 26 Feb 2021 |
Published | Nov 2021 |
Additional links |
The ability to predict malignant transformation in oral potentially malignant disorders would inform targeted treatment, provide prognostic information and allow secondary prevention. DNA ploidy and loss of heterozygosity assays are already in clinical use, and loss of heterozygosity has been used in prospective clinical trials. This review appraises published evidence of predictive ability and explores interpretation of heterogeneous studies, with different diagnostic methods, criteria and intention. Both methods have a sound biological foundation and have predictive value independent of dysplasia grading and clinical parameters. The application of these two techniques cannot be directly compared because of differences in expression of results and application to populations of different risk. Predicting malignant transformation accurately on an individual patient basis is not yet possible with either technique. However, they are valuable applications to stratify patients for inclusion in trials, identify the lowest risk patients and exclude risk when biopsy results are indeterminate for dysplasia.
King's College London - Homepage
© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454